[News Space=Reporter seungwon lee] Celltrion announced on the 14th that it participated in the '2026 JP Morgan Healthcare Conference (hereinafter referred to as JPM)' and revealed its growth strategy and business vision to global investors, thereby strengthening its position as a global new drug development company.

On the 13th (local time), Celltrion garnered significant attention from global investors by unveiling its product pipeline roadmap, including new drugs and next-generation biosimilars, and highlighting the competitiveness of its U.S. production facilities at the Main Track, the main stage of the JPM event.

Seo Jin-seok, head of Celltrion's business division, who was the first to present that day, said, "Celltrion has entered a new stage of growth as a new drug development company," and "Based on the stable cash flow secured through the biosimilar business and the antibody technology we have accumulated so far, we are actively expanding the development of new drugs."

Regarding the biosimilar business, CEO Seo stated, "We plan to expand our current portfolio of 11 biosimilar products to a total of 41 by 2038. Consequently, the targetable global market size will more than quadruple compared to last year, exceeding KRW 400 trillion." Celltrion's current biosimilar portfolio encompasses a wide range of treatment areas, including autoimmune diseases, cancer, bone diseases, and ophthalmic diseases.

The company then unveiled a development roadmap for its 16 new drug pipelines, including antibody-drug conjugates (ADCs), multiple antibodies, fetal FC receptor (FcRn) inhibitors, and obesity treatments. Among these, ADC candidates CT-P70, CT-P71, and CT-P73, as well as multiple antibody candidates CT-P72, all received Investigational New Drug (IND) approval last year and entered Phase 1 clinical trials. Key results from these four pipelines are expected to be released sequentially starting in the second half of this year.

In particular, CT-P70's recent Fast Track designation from the U.S. Food and Drug Administration (FDA) is expected to further accelerate its development. Celltrion plans to pursue Fast Track designation for other key pipeline candidates, including CT-P71, CT-P72, and CT-P73.

In addition, the new ADC candidate CT-P74 and the FcRn inhibitor CT-P77 are scheduled to submit INDs early next year, and the company plans to submit INDs for a total of 12 new drug pipelines by 2028.

The company also presented a development roadmap for its next-generation obesity treatment, CT-G32. Celltrion is developing CT-G32 using a quadruple-agent approach, with the goal of addressing interindividual variation in therapeutic efficacy and muscle loss side effects—limitations of existing treatments—as key differentiation strategies. CT-G32 is rapidly progressing development, aiming for an IND submission in the second half of next year.

CEO Seo emphasized, “We are rapidly developing new drugs through our own R&D capabilities and collaborations with global biotech companies,” and “Celltrion’s position as a new drug development company will become even more solid.”

Next, Celltrion Senior Vice President Lee Hyuk-jae highlighted the competitiveness of the Branchburg, New Jersey, production facility acquired last year and proposed plans for future facility expansion. By recently securing a production base in the US, the company has mitigated tariff risks and strengthened its global supply stability to meet its expanding product portfolio and production demand. Starting this year, the facility will be able to generate revenue through contract manufacturing organizations (CMOs), which is expected to become a new growth engine.

Celltrion plans to gradually expand its active pharmaceutical ingredient (DS) production facility from its current capacity of 66,000 liters to 99,000 liters by 2028 and by an additional 33,000 liters by 2030, bringing its total capacity to 132,000 liters. Furthermore, the company plans to establish a finished pharmaceutical product (DP) production facility to complete its end-to-end supply chain in the United States.

Celltrion plans to develop its Branchburg production facility as the foundation for its future research center in the US and a key hub for its global contract development and manufacturing organization (CDMO) business. This strategy aims to further strengthen its global market dominance by leveraging its Songdo headquarters in Korea and its US production facility as the two pillars of its strategy, while also maximizing synergy with its local research institutes.

This Senior Vice President stated, "We plan to establish our US production facility as a core production hub that generates revenue not only by supplying Celltrion products to the North American market, but also by manufacturing products for global pharmaceutical companies. Through this, we will simultaneously strengthen the stability of our global supply chain and operational efficiency." He added, "After securing the production facility, we will also pursue the establishment of a global R&D center in conjunction with a local bio cluster to secure top talent and further enhance our development competitiveness."

In addition to the official announcement, Celltrion will explore various collaboration opportunities through meetings with numerous global pharmaceutical and biotech companies and investors during the event.